Literature DB >> 15205345

Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Zhongxing Liang1, Tao Wu, Hong Lou, Xiwen Yu, Russell S Taichman, Stephen K Lau, Shuming Nie, Jay Umbreit, Hyunsuk Shim.   

Abstract

Metastasis shares many similarities with leukocyte trafficking. Among those chemokine receptors thought to be involved in hemopoietic cell homing, stromal cell-derived factor-1 and its receptor CXC chemokine receptor-4 (CXCR4) have received considerable attention. Like hemopoietic cell homing, levels of stromal cell-derived factor-1 are high at sites of breast cancer metastasis including lymph node, lung, liver, and the marrow. Moreover, CXCR4 expression is low in normal breast tissues and high in malignant tumors, suggesting that a blockade of CXCR4 might limit tumor metastasis. We therefore investigated the role of a synthetic antagonist 14-mer peptide (TN14003) in inhibiting metastasis in an animal model. Not only was TN14003 effective in limiting metastasis of breast cancer by inhibiting migration, but it may also prove useful as a diagnostic tool to identify CXCR4 receptor-positive tumor cells in culture and tumors in paraffin-embedded clinical samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205345     DOI: 10.1158/0008-5472.CAN-03-3958

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  116 in total

Review 1.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

Review 2.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

3.  Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion.

Authors:  Rubén A Bartolomé; Isabel Molina-Ortiz; Rafael Samaniego; Paloma Sánchez-Mateos; Xosé R Bustelo; Joaquin Teixidó
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 4.  Advances in microRNAs: implications for gene therapists.

Authors:  Rebecca T Marquez; Anton P McCaffrey
Journal:  Hum Gene Ther       Date:  2008-01       Impact factor: 5.695

Review 5.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.

Authors:  Élora Midavaine; Jérôme Côté; Philippe Sarret
Journal:  Cancer Metastasis Rev       Date:  2021-05-11       Impact factor: 9.264

6.  Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.

Authors:  N Cabioglu; A A Sahin; P Morandi; F Meric-Bernstam; R Islam; H Y Lin; C D Bucana; A M Gonzalez-Angulo; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 7.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 8.  Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.

Authors:  Thomas Dittmar; Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Kurt S Zänker
Journal:  Clin Exp Metastasis       Date:  2007-09-08       Impact factor: 5.150

Review 9.  Applications of neural and mesenchymal stem cells in the treatment of gliomas.

Authors:  Thomas Kosztowski; Hasan A Zaidi; Alfredo Quiñones-Hinojosa
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

10.  Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.

Authors:  Baoyao Xue; Weiguang Wu; Kan Huang; Tingting Xie; Xiaobo Xu; Hongju Zhang; Chunlei Qi; Junli Ge; Yuecheng Yu
Journal:  Mol Cell Biochem       Date:  2013-04-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.